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FT-IR spectra Figure S1 . FTIR spectrum of 5-hydroxy-3-(4-nitrophenyl)-1-(p-tolyl)-1H-pyrazole 3e. Figure S2 . FTIR spectrum of 1-(4-bromophenyl)-3-(4-nitrophenyl)-1H-pyrazole-5(4H)-one 3f. Figure S3 . FTIR spectrum of 1-(4-chlorophenyl)-3-(4-nitrophenyl)-1H-pyrazole-5(4H)-one 3g. Figure S4 . FTIR spectrum of 1-(4-bromophenyl)-3-methyl-1H-pyrazole-5(4H)-one 3h. Figure S5 . FTIR spectrum of 5-hydroxy-3-(4-nitrophenyl)-1-phenyl-4-formyl-1H-pyrazole 4d.
Figure

S6.
FTIR spectrum of N-[(1,5-dihydro-3-methyl-5-oxo-1-phenyl-4H-pyrazole-4ylidene)methyl]urea 5a. Figure S28 . LC-MS/MS spectrum of 5-hydroxy-3-(4-nitrophenyl)-1-(p-tolyl)-1H-pyrazole 3e. Figure S29 . LC-MS/MS spectrum of 1-(4-bromophenyl)-3-(4-nitrophenyl)-1H-pyrazole-5(4H)-one 3f. 
LC-MS/MS spectra
